Department of Chemical and Biomolecular Engineering, University of California, Los Angeles, USA.
J Am Chem Soc. 2009 Dec 9;131(48):17677-89. doi: 10.1021/ja907852c.
SF2575 1 is a tetracycline polyketide produced by Streptomyces sp. SF2575 and displays exceptionally potent anticancer activity toward a broad range of cancer cell lines. The structure of SF2575 is characterized by a highly substituted tetracycline aglycon. The modifications include methylation of the C-6 and C-12a hydroxyl groups, acylation of the 4-(S)-hydroxyl with salicylic acid, C-glycosylation of the C-9 of the D-ring with D-olivose and further acylation of the C4'-hydroxyl of D-olivose with the unusual angelic acid. Understanding the biosynthesis of SF2575 can therefore expand the repertoire of enzymes that can modify tetracyclines, and facilitate engineered biosynthesis of SF2575 analogues. In this study, we identified, sequenced, and functionally analyzed the ssf biosynthetic gene cluster which contains 40 putative open reading frames. Genes encoding enzymes that can assemble the tetracycline aglycon, as well as installing these unique structural features, are found in the gene cluster. Biosynthetic intermediates were isolated from the SF2575 culture extract to suggest the order of pendant-group addition is C-9 glycosylation, C-4 salicylation, and O-4' angelylcylation. Using in vitro assays, two enzymes that are responsible for C-4 acylation of salicylic acid were identified. These enzymes include an ATP-dependent salicylyl-CoA ligase SsfL1 and a putative GDSL family acyltransferase SsfX3, both of which were shown to have relaxed substrate specificity toward substituted benzoic acids. Since the salicylic acid moiety is critically important for the anticancer properties of SF2575, verification of the activities of SsfL1 and SsfX3 sets the stage for biosynthetic modification of the C-4 group toward structure-activity relationship studies of SF2575. Using heterologous biosynthesis in Streptomyces lividans, we also determined that biosynthesis of the SF2575 tetracycline aglycon 8 parallels that of oxytetracycline 4 and diverges after the assembly of 4-keto-anhydrotetracycline 51. The minimal ssf polyketide synthase together with the amidotransferase SsfD produced the amidated decaketide backbone that is required for the formation of 2-naphthacenecarboxamide skeleton. Additional enzymes, such as cyclases C-6 methyltransferase and C-4/C-12a dihydroxylase, were functionally reconstituted.
SF2575 1 是一种由链霉菌 SF2575 产生的四环素聚酮化合物,对广泛的癌细胞系表现出异常强大的抗癌活性。SF2575 的结构特点是高度取代的四环素糖苷配基。修饰包括 C-6 和 C-12a 羟基的甲基化、4-(S)-羟基与水杨酸的酰化、D-环的 C-9 与 D-橄榄糖的 C-糖苷化以及 D-橄榄糖的 C4'-羟基与异常当归酸的进一步酰化。因此,了解 SF2575 的生物合成可以扩展能够修饰四环素的酶的 repertoire,并促进 SF2575 类似物的工程生物合成。在这项研究中,我们鉴定、测序并功能分析了 ssf 生物合成基因簇,该基因簇包含 40 个推定的开放阅读框。基因簇中发现了能够组装四环素糖苷配基以及安装这些独特结构特征的酶编码基因。从 SF2575 培养物提取物中分离出生物合成中间体,提示侧链基团添加的顺序为 C-9 糖基化、C-4 水杨酸化和 O-4'当归酰化。使用体外测定法,鉴定出负责水杨酸 C-4 酰化的两种酶。这些酶包括一个 ATP 依赖性水杨酸-CoA 连接酶 SsfL1 和一个假定的 GDSL 家族酰基转移酶 SsfX3,它们都对取代苯甲酸表现出宽松的底物特异性。由于水杨酸部分对于 SF2575 的抗癌特性至关重要,因此验证 SsfL1 和 SsfX3 的活性为 C-4 基团的生物合成修饰奠定了基础,可用于 SF2575 的结构-活性关系研究。通过链霉菌 lividans 的异源生物合成,我们还确定 SF2575 四环素糖苷配基 8 的生物合成与土霉素 4 的生物合成平行,在装配 4-酮-脱水四环素 51 后发生分歧。最小的 ssf 聚酮合酶与氨酰转移酶 SsfD 一起产生酰胺化的十肽骨架,这是形成 2-萘甲酰胺骨架所必需的。还功能重建了其他酶,如环化酶 C-6 甲基转移酶和 C-4/C-12a 二羟化酶。